Clinical Trial Update: A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for GRNVAC1 active immunotherapy in acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• GRNVAC1 (GRNVAC1)

Snippet

Sponsor: Asterias Biotherapeutics, Inc. | Conditions: Acute Myelogenous Leukemia | Phase 2 | Status: COMPLETED